Female Sexual Dysfunction
Conditions
Keywords
dorsal genital nerve stimulation, neuromodulation
Brief summary
This pilot study investigates the regular use of non-invasive dorsal genital nerve stimulation (DGS) for the treatment of female sexual dysfunction (FSD). The researchers aim to determine whether subjects with FSD can correctly follow an at-home treatment regimen and to demonstrate that DGS can improve FSD arousal symptoms in premenopausal and postmenopausal women. Some subjects will use a smart vibrator for comparison to DGS.
Interventions
DEVICEElectrical Stimulation
Electrical stimulation of the dorsal genital nerve will be accomplished using the UCon system and patch electrodes developed by InnoCon. The UCon system includes a programmable control unit; leads that connect to the control unit and electrodes; a silicone surface electrode; a reference electrode; and a remote control for quick on and off toggling of stimulation.
DEVICESmart vibrator
Subjects will use a smart vibrator at home twice a week during the study. The Lioness smart vibrator records physiological responses during use.
Sponsors
University of Michigan
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Capable of speaking and understanding English. * Able to comprehend the clinical study procedures and provide informed consent. * Identified as having female sexual dysfunction with a Female Sexual Function Index (FSFI) score of 26.55 or less and a score of 3 or less on one or more of the FSFI subdomains of lubrication, arousal, and orgasm. * Willing and able to adhere to the study protocol * Able to attend experimental sessions at Michigan Medicine at both the start and conclusion of the study.
Exclusion criteria
* Not currently sexually active. * Pregnant or planning to get pregnant during the study period. * History of a neurological disorder or impairments affecting pelvic organ function, including diagnosed with dorsal genital nerve damage, lower motor dysfunction, or other related conditions. * Implanted with a neurostimulator for bladder or bowel function. * Have a skin condition that would predispose them to sensitivity to the stimulation electrodes. * Female sexual dysfunction limited solely to low desire, without issues in lubrication, arousal, or orgasm. * Clinically diagnosed bladder dysfunction, pelvic pain, or other pelvic organ symptoms; or a score of 8 or higher on the American Urological Association Symptom Index (AUASI). * Unable or unwilling to adhere to the study protocol * Simultaneously participating in another research study that may affect the results of this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of dorsal genital nerve stimulation (DGS) sessions performed | Approximately day 22 | — |
| Number of related adverse events | Up to week 9 | Study-related AEs include incidents such as device zapping, skin irritation, back cramps, or falls due to sitting for 30 minutes of stimulation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Female Sexual Function Index (FSFI) total scores | Baseline and approximately day 22 | The FSFI is a 19-question survey assessing sexual function in 6 different domains (desire, arousal, lubrication, orgasm, satisfaction, and pain). Each question asks subjects to rate an aspect of their sexual function on a scale from 0 or 1 to 5, depending on the question. The total score for each subdomain is multiplied by a factor so that the maximum score is 6. The total score is out of 36, with the cutoff score for overall dysfunction being 26.55. Subdomain scores of 3 or less indicate dysfunction in the respective subdomain. The FSFI will be conducted before the first study visit and again within one week after completion of the at-home stimulation period in order to see if scores have changed over the course of the treatment. |
| The Patient Global Impression of Change (PGIC) survey score | Up to week 9 | The Patient Global Impression of Change (PGIC) is a 1-question survey asking patients to describe the change in their condition with a number from 1 to 7. Each number is paired with a description, where 1 represents No change (or condition is worse) and 7 represents A great deal better, and a considerable improvement that has made all the difference. The PGIC will be administered within one week after completion of at-home stimulation, and again 1 month later in order to assess the patient's perception of their change in symptoms. |
Countries
United States
Contacts
Primary ContactYike Liu
Backup ContactTim Bruns, PhD
Outcome results
None listed